[
  {
    "ts": null,
    "headline": "Biogen Inc. stock underperforms Wednesday when compared to competitors",
    "summary": "Biogen Inc. stock underperforms Wednesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=b3384c9451365701847abfc71871cc240539f9cc18fc2cab5ab8d9e51af70931",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741799160,
      "headline": "Biogen Inc. stock underperforms Wednesday when compared to competitors",
      "id": 133254675,
      "image": "",
      "related": "BIIB",
      "source": "MarketWatch",
      "summary": "Biogen Inc. stock underperforms Wednesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=b3384c9451365701847abfc71871cc240539f9cc18fc2cab5ab8d9e51af70931"
    }
  },
  {
    "ts": null,
    "headline": "BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant",
    "summary": "BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients.",
    "url": "https://finnhub.io/api/news?id=19a27ed80ed2ea9b06cc5af44147043a2de6ed981e306358ea3b37dd855c8749",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741795920,
      "headline": "BIIB Starts Felzartamab Phase III Study in AMR in Kidney Transplant",
      "id": 133191250,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "BIIB's TRANSCEND phase III study on felzartamab in adult kidney transplant recipients diagnosed with late AMR is set to enroll approximately 120 patients.",
      "url": "https://finnhub.io/api/news?id=19a27ed80ed2ea9b06cc5af44147043a2de6ed981e306358ea3b37dd855c8749"
    }
  },
  {
    "ts": null,
    "headline": "Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR",
    "summary": "In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.",
    "url": "https://finnhub.io/api/news?id=df483530e6c6ec9628ca2140df1d11a3209339b128ea65778b2593da11d334ea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1741780047,
      "headline": "Biogen begins dosing in trial of felzartamab for kidney transplant patients with AMR",
      "id": 133191251,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "In Part A of the trial, subjects will be given nine intravenous infusions of either the drug or placebo over a six-month period.",
      "url": "https://finnhub.io/api/news?id=df483530e6c6ec9628ca2140df1d11a3209339b128ea65778b2593da11d334ea"
    }
  }
]